Open AccessThe Effects of an Olmesartan Medoxomil–Based Treatment Algorithm on 24‐Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older
Author(s) -
Kereiakes Dean J.,
Neutel Joel,
Stoakes Kathy A.,
Waverczak William F.,
Xu Jianbo,
Shojaee Ali,
Dubiel Robert
Publication year - 2009
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2009.00147.x
Subject(s) - medicine , olmesartan , hydrochlorothiazide , ambulatory blood pressure , tolerability , blood pressure , placebo , ambulatory , adverse effect , dosing , population , anesthesia , alternative medicine , environmental health , pathology
This study examined the effect of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) on mean 24‐hour ambulatory blood pressure, mean seated cuff (Se) blood pressure (BP), and SeBP goal achievement in elderly (65 years and older) patients with hypertension. After a 2‐ to 3‐week placebo run‐in period, patients received OM 20 mg, up‐titrated to OM 40 mg, and then added HCTZ 12.5 mg to 25 mg in a stepwise manner at 3‐week intervals if SeBP remained ≥120/70 mm Hg. The primary end point was change from baseline in mean 24‐hour ambulatory systolic BP. At study end, mean 24‐hour ambulatory BP had decreased by 25.7/12.3 mm Hg (n=150) and mean SeBP by 25.4/10.5 mm Hg (n=176; all P <.00001 vs baseline). Drug‐related treatment‐emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), were observed in 11.8% of patients. An OM‐based treatment algorithm effectively lowers BP in an elderly patient population throughout the 24‐hour dosing interval without compromising tolerability.